AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 63 min read$HROW

HARROW, INC. (HROW): Entry into a Material Definitive Agreement

HARROW, INC. (HROW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001360214 0001360214 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:36 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$HROW
Bullish
medium confidence
Mentioned
$HROW
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HROWBullishMed
01

Why it matters

The filing provides deal structure (cash at closing plus milestone payments), asset scope (NDA, IP, inventory, contracts), and key execution risks (closing conditions, potential non-completion).

02

Market read

Traders can update deal-driven expectations for Harrow’s future cash flows and risk, with the main uncertainty centered on closing timing and milestone attainment.

03

What to watch

Closing is subject to customary conditions and timing is uncertain; any delays or required regulatory/contractual steps could defer value realization and increase execution risk.

Relevance 6/10Novelty 8/10Timing: deal announced via 8-K today, closing expected in 2H 2026

Background

Harrow (HROW) filed an 8-K describing an Asset Purchase Agreement with Viatris to acquire global rights to TYRVAYA nasal spray for dry eye disease.

Company-level read

Ticker impact

$HROWBullishMedium confidence
Context

Harrow entered an asset purchase agreement to acquire global rights to TYRVAYA, paying $30M cash plus up to $70M in milestones.

Expected impact

Likely positive re-rating on deal announcement, with follow-through dependent on deal closing progress and milestone outlook.

Evidence & confidence

The 8-K discloses concrete consideration ($30M cash, up to $70M contingent) and the asset scope (NDA, IP, inventory, contracts), which can materially affect expectations for Harrow’s future revenue and risk profile.

Market effects

Sector

Signals continued consolidation in ophthalmology/respiratory specialty pharma around established branded assets and milestone-based economics.

Regional

Primarily US-listed pharma sentiment; limited direct regional spillover beyond specialty pharma investors.

Global

Global rights acquisition suggests cross-border commercialization and regulatory transfer considerations, but no additional jurisdictions are specified.

Counterpoint

What could challenge this read

The $70M is contingent on net sales thresholds, so the headline economics may overstate near-term earnings impact if TYRVAYA sales underperform.

Key entities

  • public_company
    Harrow, Inc.

    US-listed acquirer entering an asset purchase agreement for TYRVAYA global rights.

  • public_company
    Viatris Inc.

    Seller providing TYRVAYA assets and related regulatory/IP materials to Harrow.

  • product_asset
    TYRVAYA (varenicline solution) nasal spray 0.03 mg

    Cholinergic agonist indicated for dry eye disease; acquisition includes NDA and approvals.

Read at source← All news

Related articles

AUG 13
$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

yahoo.com6 min
AUG 10
$HROWMed

HARROW, INC. (HROW): Results of Operations and Financial Condition

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28 th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand into revenue and profits

SEC EDGAR 8-K7 min
JUL 1
$HROWMed

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow (Nasdaq: HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, for wet AMD, RVO macular edema, and mCNV. The launch follows Harrow’s exclusive U.S. commercialization agreement with Samsung Bioepis. Harrow also noted exclusive U.S. rights to OPUVIZ (aflibercept-yszy).

manilatimes.net4 min
AUG 13
$MSTRMedAI 8/10

Strategy Sells 1,690 Bitcoin as USD Reserve Hits $4.65 Billion

Strategy (MSTR) sold 1,690 BTC for $108.6 million in the week ending Aug. 9, per an SEC Form 8-K. BTC sold averaged $64,262 versus an average cost basis of $75,385. Afterward it held 840,447 BTC. Proceeds funded a $108.6 million STRC preferred buyback and Strategy also raised $653.1 million net via an MSTR ATM offering.

memeburn.com6 min
AUG 13
$TLSMed

Telstra FY profit rises slightly, announces $706 mln buyback

Telstra Group reported FY profit attributable of A$2.24 billion, up 3.2% year over year, citing growth in mobile operations and higher customer spending. Mobile revenue rose 3.2% to A$11.37 billion. Telstra announced an A$1 billion share buyback and forecast 2027 EBIT after leases of A$8.5–A$8.8 billion, plus cash EBIT of A$4.75–A$4.95 billion. Final dividend was 10.5 Australian cents.

investing.com2 min